ClinicalTrials.gg
CompletedNCT02873936FINCH 2Updated May 13, 2021Results posted

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

A Phase 3 interventional study of Filgotinib and Placebo to match filgotinib in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 104 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
6th of 17
449 · median 287
Started
2016
with 2 others
Phase 3
5 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
5 of 17
Gilead Sciences

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a diagnosis of RA (2010 American College of Rheumatology [ACR]/European League Against Rheumatism [EULAR] criteria for RA), and are ACR functional class I-III.
  • Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints [SJC66]) and ≥6 tender joints (from a tender joint count based on 68 joints [TJC68]) at screening and Day 1
  • Ongoing treatment with a stable prescription of 1 or 2 csDMARDs
  • Have received at least one biologic disease modifying antirheumatic drug (bDMARD) for the treatment of RA to which they have had an inadequate response or intolerance

Key Exclusion Criteria:

  • Previous treatment with any janus kinase (JAK) inhibitor

NOTE: Other protocol Inclusion/ Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
449 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg

    Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)

    Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: csDMARDs

  • Experimental
    Filgotinib 100 mg

    Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)

    Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: csDMARDs

  • Placebo comparator
    Placebo

    Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)

    Drug: Placebo to match filgotinib · Drug: csDMARDs

Interventions

  • Tablet(s) administered orally once daily

    Also known as: GS-6034

  • DrugPlacebo to match filgotinib

    Tablet(s) administered orally once daily

  • DrugcsDMARDs

    csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12

    ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0-3 \[0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices\]. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled)\] when 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. Negative change from baseline indicates improvement (less disability).

    Time frame: Baseline; Week 12

  2. Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] ≤ 3.2 at Week 12

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP=hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Week 12

  3. Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Week 12

  4. Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Week 24

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Week 24

  5. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

    Time frame: Baseline; Week 12

  6. Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 4, 12, and 24

    ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 4, 12, and 24

  7. Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24

    ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 4, 12, and 24

  8. Percentage of Participants Who Achieved ACR20 Response at Weeks 4, and 24

    ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 4, and 24

  9. Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 4, 12, and 24

    TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  10. Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 4, 12, and 24

    The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  11. Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 4, 12, and 24

    SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  12. Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 4, 12, and 24

    PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 3 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  13. Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 4, 12, and 24

    The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  14. Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 4, and 24

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, and 24

  15. Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 4, 12, and 24

    Time frame: Baseline; Weeks 4, 12, and 24

  16. Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 4, 12, and 24

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 4, 12, and 24

  17. Change From Baseline in DAS28 (CRP) at Weeks 4, 12, and 24

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  18. Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 4, and 24

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 4, and 24

  19. Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 4, and 12

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 4, and 12

  20. American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 4, 12, and 24

    ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.

    Time frame: Weeks 4, 12, and 24

  21. Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24

    Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.

    Time frame: Weeks 4, 12, and 24

  22. Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, and 24

    CDAI is calculated using formula: CDAI = TJC based on 28 joints (TJC28) + SJC based on 28 joints (SJC28) + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  23. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, and 24

    SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  24. SF-36 PCS Score at Weeks 4, 12, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

    Time frame: Weeks 4, 12, and 24

  25. Change From Baseline in SF-36 PCS Score at Weeks 4, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Weeks 4, and 24

  26. SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

    Time frame: Weeks 4, 12, and 24

  27. Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Weeks 4, 12, and 24

  28. FACIT-Fatigue Score at Weeks 4, 12, and 24

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.

    Time frame: Weeks 4, 12, and 24

  29. Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

    Time frame: Baseline; Weeks 4, and 24

  30. Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24

    The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

    Time frame: Weeks 4, 12, and 24

  31. EQ-5D Current Health VAS at Weeks 4, 12, and 24

    EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

    Time frame: Weeks 4, 12, and 24

  32. Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24

    The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).

    Time frame: Baseline; Weeks 4, 12, and 24

  33. Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  34. WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  35. WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  36. WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  37. Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  38. Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  39. Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  40. Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

07

Results

Posted Jan 15, 2021

Participant flow

Participants were enrolled at study sites in Australia, Asia, Europe, North America, and South America. The first participant was screened on 27 July 2016. The last study visit occurred on 26 June 2018.

Participant flow — Overall Study
MilestoneFilgotinib 200 mgFilgotinib 100 mgPlacebo
Started148153148
Completed135130116
Not completed132332
Withdrew: Withdrew consent41120
Withdrew: Investigator's discretion354
Withdrew: Adverse event353
Withdrew: Protocol violation013
Withdrew: Lost to follow-up111
Withdrew: Non-compliance with study drug101
Withdrew: Randomized but not dosed100

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 1266.0 (58.0 to 74.0)57.5 (49.4 to 65.7)31.1 (23.3 to 38.9)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 34.9 · 95% CI 23.5 to 46.3
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 26.4 · 95% CI 15.0 to 37.9
SecondaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0-3 \[0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices\]. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled)\] when 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. Negative change from baseline indicates improvement (less disability).

Time frame:
Baseline; Week 12
Reported as:
Mean · score on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline1.70 ± 0.6561.64 ± 0.6831.65 ± 0.633
Change from Baseline at Week 12-0.55 ± 0.590-0.48 ± 0.602-0.23 ± 0.547
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.32 · 95% CI -0.45 to -0.19
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.27 · 95% CI -0.40 to -0.14
SecondaryPercentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] ≤ 3.2 at Week 12

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP=hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] ≤ 3.2 at Week 12
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] ≤ 3.2 at Week 1240.8 (32.5 to 49.1)37.3 (29.3 to 45.2)15.5 (9.4 to 21.7)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 25.3 · 95% CI 14.7 to 35.8
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 21.7 · 95% CI 11.4 to 32.0
SecondaryChange From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Week 12
Reported as:
Mean · score on a scale
Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline30.4 ± 7.7531.7 ± 7.7631.1 ± 8.17
Change from Baseline at Week 127.6 ± 7.686.8 ± 8.223.6 ± 8.16
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 4.3 · 95% CI 2.5 to 6.1
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.4 · 95% CI 1.6 to 5.2
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Week 24

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Week 2430.6 (22.8 to 38.4)26.1 (18.9 to 33.4)12.2 (6.6 to 17.8)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 18.5 · 95% CI 8.6 to 28.3
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.003 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 14.0 · 95% CI 4.6 to 23.4
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

Time frame:
Baseline; Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline24.2 ± 11.4723.7 ± 12.3025.4 ± 10.89
Change from Baseline at Week 129.6 ± 11.248.3 ± 10.804.5 ± 10.37
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 5.0 · 95% CI 2.6 to 7.3
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.007 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.2 · 95% CI 0.9 to 5.5
SecondaryPercentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 4, 12, and 24

ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 4, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 4, 12, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 422.4 (15.4 to 29.5)21.6 (14.7 to 28.4)7.4 (2.9 to 12.0)
Week 1242.9 (34.5 to 51.2)32.0 (24.3 to 39.7)14.9 (8.8 to 20.9)
Week 2445.6 (37.2 to 54.0)35.3 (27.4 to 43.2)18.9 (12.3 to 25.6)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 15.0 · 95% CI 6.4 to 23.7
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 14.1 · 95% CI 5.7 to 22.6
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 28.0 · 95% CI 17.5 to 38.5
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 17.2 · 95% CI 7.1 to 27.2
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 26.7 · 95% CI 15.8 to 37.6
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.002 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 16.4 · 95% CI 5.9 to 26.9
SecondaryPercentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24

ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 4, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 46.1 (1.9 to 10.3)8.5 (3.8 to 13.2)2.7 (0.0 to 5.7)
Week 1221.8 (14.8 to 28.8)14.4 (8.5 to 20.3)6.8 (2.4 to 11.1)
Week 2432.0 (24.1 to 39.9)20.3 (13.6 to 27.0)8.1 (3.4 to 12.8)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = 0.16 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 3.4 · 95% CI -1.9 to 8.8
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.039 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 5.8 · 95% CI -0.0 to 11.6
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 15.0 · 95% CI 6.5 to 23.5
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.036 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 7.6 · 95% CI 0.1 to 15.2
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 23.9 · 95% CI 14.5 to 33.3
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.004 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 12.2 · 95% CI 3.7 to 20.6
SecondaryPercentage of Participants Who Achieved ACR20 Response at Weeks 4, and 24

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 4, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR20 Response at Weeks 4, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 451.7 (43.3 to 60.1)44.4 (36.2 to 52.6)25.7 (18.3 to 33.1)
Week 2469.4 (61.6 to 77.2)54.9 (46.7 to 63.1)34.5 (26.5 to 42.5)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 26.0 · 95% CI 14.6 to 37.4
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 18.8 · 95% CI 7.5 to 30.0
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 34.9 · 95% CI 23.6 to 46.3
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 20.4 · 95% CI 8.8 to 32.1
SecondaryChange From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 4, 12, and 24

TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · tender joint count
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 4, 12, and 24
tender joint countFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline28.0 ± 16.126.0 ± 15.427.0 ± 15.5
Change from Baseline at Week 4-13.0 ± 13.5-11.0 ± 11.0-8.0 ± 13.8
Change from Baseline at Week 12-18.0 ± 14.1-16.0 ± 11.8-12.0 ± 13.4
Change from Baseline at Week 24-22.0 ± 14.2-19.0 ± 13.0-17.0 ± 13.3
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.003 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.0 · 95% CI -7.0 to -1.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.027 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.0 · 95% CI -6.0 to -0.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.0 · 95% CI -8.0 to -3.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.0 · 95% CI -7.0 to -2.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.0 · 95% CI -10.0 to -4.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.006 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.0 · 95% CI -7.0 to -1.0
SecondaryChange From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 4, 12, and 24

The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · swollen joint count
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 4, 12, and 24
swollen joint countFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline18.0 ± 12.517.0 ± 12.417.0 ± 9.7
Change from Baseline at Week 4-10.0 ± 10.6-7.0 ± 9.2-7.0 ± 8.8
Change from Baseline at Week 12-12.0 ± 10.5-10.0 ± 8.6-8.0 ± 8.9
Change from Baseline at Week 24-14.0 ± 10.3-13.0 ± 10.0-12.0 ± 8.7
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.008 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.0 · 95% CI -5.0 to -1.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.65 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.0 · 95% CI -2.0 to 1.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.0 · 95% CI -5.0 to -2.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.008 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -4.0 to -1.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.0 · 95% CI -5.0 to -2.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.039 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -4.0 to -0.0
SecondaryChange From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 4, 12, and 24

SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline68.0 ± 20.669.0 ± 20.270.0 ± 18.0
Change from Baseline at Week 4-21.0 ± 23.2-20.0 ± 26.1-10.0 ± 22.6
Change from Baseline at Week 12-31.0 ± 25.9-27.0 ± 28.4-14.0 ± 26.3
Change from Baseline at Week 24-38.0 ± 26.8-34.0 ± 28.1-24.0 ± 28.0
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -12.0 · 95% CI -17.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -11.0 · 95% CI -16.0 to -5.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -18.0 · 95% CI -24.0 to -12.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -13.0 · 95% CI -19.0 to -7.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -18.0 · 95% CI -25.0 to -12.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -13.0 · 95% CI -19.0 to -6.0
SecondaryChange From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 4, 12, and 24

PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 3 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline69.0 ± 17.668.0 ± 18.766.0 ± 16.7
Change from Baseline at Week 4-32.0 ± 25.2-30.0 ± 24.3-19.0 ± 22.2
Change from Baseline at Week 12-45.0 ± 25.2-41.0 ± 26.7-28.0 ± 26.9
Change from Baseline at Week 24-53.0 ± 22.7-45.0 ± 23.8-41.0 ± 23.5
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Mixed effects model for repeated measure · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -12.0 · 95% CI -17.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.0 · 95% CI -15.0 to -5.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -16.0 · 95% CI -22.0 to -11.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -13.0 · 95% CI -18.0 to -7.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -13.0 · 95% CI -18.0 to -8.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.052 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.0 · 95% CI -11.0 to 0.0
SecondaryChange From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 4, 12, and 24

The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline66.0 ± 21.667.0 ± 21.768.0 ± 19.9
Change from Baseline at Week 4-22.0 ± 24.2-20.0 ± 26.3-8.0 ± 22.6
Change from Baseline at Week 12-30.0 ± 27.9-27.0 ± 30.9-14.0 ± 27.0
Change from Baseline at Week 24-37.0 ± 28.1-35.0 ± 29.1-24.0 ± 28.3
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -16.0 · 95% CI -21.0 to -10.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -14.0 · 95% CI -19.0 to -8.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -17.0 · 95% CI -23.0 to -11.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -13.0 · 95% CI -19.0 to -7.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -16.0 · 95% CI -23.0 to -10.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -12.0 · 95% CI -19.0 to -5.0
SecondaryChange From Baseline in Individual ACR Component: HAQ-DI at Weeks 4, and 24

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 4, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline1.70 ± 0.6561.64 ± 0.6831.65 ± 0.633
Change from Baseline at Week 4-0.39 ± 0.493-0.32 ± 0.539-0.18 ± 0.444
Change from Baseline at Week 24-0.75 ± 0.620-0.60 ± 0.660-0.42 ± 0.600
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.22 · 95% CI -0.33 to -0.11
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.006 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.15 · 95% CI -0.26 to -0.04
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.36 · 95% CI -0.51 to -0.21
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.003 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.22 · 95% CI -0.37 to -0.08
SecondaryChange From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 4, 12, and 24
Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · mg/L
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 4, 12, and 24
mg/LFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline17.21 ± 18.27521.49 ± 28.20616.42 ± 18.321
Change from Baseline at Week 4-9.55 ± 18.421-12.15 ± 25.5021.04 ± 13.942
Change from Baseline at Week 12-11.86 ± 19.760-12.02 ± 26.2260.57 ± 15.178
Change from Baseline at Week 24-10.87 ± 19.083-11.12 ± 27.766-1.50 ± 15.889
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.51 · 95% CI -13.61 to -7.41
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.92 · 95% CI -12.02 to -5.82
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.94 · 95% CI -14.19 to -7.69
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.98 · 95% CI -12.22 to -5.73
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.87 · 95% CI -13.73 to -6.00
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.89 · 95% CI -10.80 to -2.98
SecondaryPercentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 4, 12, and 24

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 4, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 4, 12, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 460.4 (52.1 to 68.8)54.7 (46.4 to 63.1)40.3 (31.9 to 48.6)
Week 1266.7 (58.6 to 74.7)66.2 (58.3 to 74.2)44.4 (36.0 to 52.9)
Week 2468.8 (60.8 to 76.7)54.1 (45.7 to 62.4)35.4 (27.3 to 43.6)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 20.1 · 95% CI 8.1 to 32.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.013 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 14.5 · 95% CI 2.4 to 26.5
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 22.2 · 95% CI 10.3 to 34.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 21.8 · 95% CI 10.0 to 33.6
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 33.3 · 95% CI 21.8 to 44.9
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 18.6 · 95% CI 6.8 to 30.5
SecondaryChange From Baseline in DAS28 (CRP) at Weeks 4, 12, and 24

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in DAS28 (CRP) at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline5.9 ± 1.035.9 ± 0.985.9 ± 0.86
Change from Baseline at Week 4-1.7 ± 1.16-1.5 ± 1.14-0.9 ± 1.14
Change from Baseline at Week 12-2.4 ± 1.32-2.3 ± 1.38-1.3 ± 1.33
Change from Baseline at Week 24-2.9 ± 1.29-2.6 ± 1.32-2.1 ± 1.28
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.9 · 95% CI -1.1 to -0.6
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.7 · 95% CI -0.9 to -0.4
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.2 · 95% CI -1.5 to -0.9
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.0 · 95% CI -1.3 to -0.7
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.1 · 95% CI -1.5 to -0.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.7 · 95% CI -1.1 to -0.4
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 4, and 24

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 4, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 4, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 421.8 (14.8 to 28.8)22.2 (15.3 to 29.1)9.5 (4.4 to 14.5)
Week 2448.3 (39.9 to 56.7)37.9 (29.9 to 45.9)20.9 (14.1 to 27.8)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = 0.004 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 12.3 · 95% CI 3.5 to 21.2
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.003 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 12.8 · 95% CI 4.0 to 21.5
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 27.4 · 95% CI 16.3 to 38.4
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 17.0 · 95% CI 6.2 to 27.7
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 4, and 12

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 4, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 4, and 12
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 410.2 (5.0 to 15.4)11.8 (6.3 to 17.2)2.7 (0.0 to 5.7)
Week 1222.4 (15.4 to 29.5)25.5 (18.3 to 32.7)8.1 (3.4 to 12.8)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = 0.012 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 7.5 · 95% CI 1.3 to 13.7
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.006 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 9.1 · 95% CI 2.7 to 15.5
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 14.3 · 95% CI 5.6 to 23.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 17.4 · 95% CI 8.5 to 26.2
SecondaryAmerican College of Rheumatology N Percent Improvement (ACR-N) at Weeks 4, 12, and 24

ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percent improvement
American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 4, 12, and 24
percent improvementFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 426.9 ± 24.5825.8 ± 27.0913.7 ± 19.42
Week 1243.4 ± 29.2637.1 ± 30.2919.7 ± 25.44
Week 2453.5 ± 27.5245.5 ± 32.1631.9 ± 29.52
SecondaryNumber of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24

Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.

Time frame:
Weeks 4, 12, and 24
Reported as:
Count of participants · Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
ParticipantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 4 — Good Response323413
Week 4 — Moderate Response746553
Week 4 — No Response384663
Week 12 — Good Response585623
Week 12 — Moderate Response655851
Week 12 — No Response132354
Week 24 — Good Response705831
Week 24 — Moderate Response434745
Week 24 — No Response8612
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, and 24

CDAI is calculated using formula: CDAI = TJC based on 28 joints (TJC28) + SJC based on 28 joints (SJC28) + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline41.7 ± 14.2340.4 ± 13.2341.4 ± 12.00
Change from Baseline at Week 4-19.1 ± 13.06-16.8 ± 12.95-12.8 ± 13.71
Change from Baseline at Week 12-26.2 ± 15.04-23.8 ± 14.33-17.3 ± 15.22
Change from Baseline at Week 24-30.9 ± 13.77-27.8 ± 13.54-25.4 ± 14.40
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.1 · 95% CI -10.0 to -4.2
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.0 · 95% CI -7.9 to -2.2
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.5 · 95% CI -12.6 to -6.5
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.6 · 95% CI -10.6 to -4.5
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.7 · 95% CI -11.9 to -5.5
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.003 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.9 · 95% CI -8.2 to -1.6
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, and 24

SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline43.4 ± 14.6442.6 ± 14.1643.0 ± 12.33
Change from Baseline at Week 4-20.1 ± 13.73-18.1 ± 13.19-12.9 ± 14.01
Change from Baseline at Week 12-27.6 ± 15.54-24.9 ± 15.01-17.2 ± 15.52
Change from Baseline at Week 24-32.1 ± 14.41-28.8 ± 14.19-24.9 ± 14.84
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.1 · 95% CI -11.1 to -5.1
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.9 · 95% CI -8.9 to -2.9
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.7 · 95% CI -13.8 to -7.5
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.7 · 95% CI -11.8 to -5.5
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.1 · 95% CI -13.5 to -6.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.1 · 95% CI -9.4 to -2.7
SecondarySF-36 PCS Score at Weeks 4, 12, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
SF-36 PCS Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 435.4 ± 8.7236.4 ± 9.2933.7 ± 8.67
Week 1238.3 ± 10.1438.6 ± 9.3935.1 ± 9.90
Week 2440.4 ± 9.6440.3 ± 10.3137.7 ± 9.09
SecondaryChange From Baseline in SF-36 PCS Score at Weeks 4, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Weeks 4, and 24
Reported as:
Mean · score on a scale
Change From Baseline in SF-36 PCS Score at Weeks 4, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline30.4 ± 7.7531.7 ± 7.7631.1 ± 8.17
Change from Baseline at Week 45.1 ± 6.344.5 ± 6.532.5 ± 5.91
Change from Baseline at Week 249.4 ± 8.239.0 ± 8.446.6 ± 7.95
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.5 · 95% CI 1.1 to 3.9
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.005 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.0 · 95% CI 0.6 to 3.4
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.9 · 95% CI 1.9 to 5.9
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.002 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.1 · 95% CI 1.1 to 5.2
SecondarySF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 448.0 ± 11.4847.3 ± 11.5145.5 ± 11.11
Week 1250.2 ± 10.5848.8 ± 11.0247.9 ± 11.01
Week 2450.6 ± 10.3549.5 ± 10.7249.1 ± 10.56
SecondaryChange From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline44.5 ± 11.9744.2 ± 11.5944.3 ± 11.32
Change from Baseline at Week 43.5 ± 9.173.0 ± 9.031.2 ± 9.34
Change from Baseline at Week 125.3 ± 10.604.6 ± 9.763.7 ± 9.17
Change from Baseline at Week 246.5 ± 12.504.6 ± 9.224.3 ± 9.44
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.019 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.3 · 95% CI 0.4 to 4.2
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.073 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.7 · 95% CI -0.2 to 3.6
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.045 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.1 · 95% CI 0.0 to 4.1
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.32 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.0 · 95% CI -1.0 to 3.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.12 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.9 · 95% CI -0.5 to 4.2
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.96 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 0.1 · 95% CI -2.3 to 2.4
SecondaryFACIT-Fatigue Score at Weeks 4, 12, and 24

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
FACIT-Fatigue Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 430.4 ± 12.4830.3 ± 12.3027.9 ± 11.29
Week 1234.0 ± 12.0832.1 ± 13.6630.4 ± 11.79
Week 2436.3 ± 11.5834.4 ± 12.5133.3 ± 11.26
SecondaryChange From Baseline in FACIT-Fatigue Score at Weeks 4, and 24

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

Time frame:
Baseline; Weeks 4, and 24
Reported as:
Mean · score on a scale
Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline24.2 ± 11.4723.7 ± 12.3025.4 ± 10.89
Change from Baseline at Week 46.2 ± 10.206.4 ± 9.872.2 ± 8.92
Change from Baseline at Week 2411.6 ± 11.679.8 ± 10.397.0 ± 10.23
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.7 · 95% CI 1.6 to 5.7
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.002 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.3 · 95% CI 1.2 to 5.4
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 4.6 · 95% CI 2.1 to 7.1
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.11 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.1 · 95% CI -0.5 to 4.7
SecondaryNumber of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24

The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Time frame:
Weeks 4, 12, and 24
Reported as:
Count of participants · Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
ParticipantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Mobility: Week 4 — No Problems344532
Mobility: Week 4 — Slight Problems584949
Mobility: Week 4 — Moderate Problems383336
Mobility: Week 4 — Severe Problems151625
Mobility: Week 4 — Extreme Problems012
Mobility: Week 12 — No Problems475738
Mobility: Week 12 — Slight Problems554846
Mobility: Week 12 — Moderate Problems252929
Mobility: Week 12 — Severe Problems13919
Mobility: Week 12 — Extreme Problems100
Mobility: Week 24 — No Problems513832
Mobility: Week 24 — Slight Problems384529
Mobility: Week 24 — Moderate Problems231824
Mobility: Week 24 — Severe Problems1185
Mobility: Week 24 — Extreme Problems010
Self-care: Week 4 — No Problems676749
Self-care: Week 4 — Slight Problems454352
Self-care: Week 4 — Moderate Problems242728
Self-care: Week 4 — Severe Problems6611
Self-care: Week 4 — Extreme Problems314
Self-care: Week 12 — No Problems797856
Self-care: Week 12 — Slight Problems384644
Self-care: Week 12 — Moderate Problems161521
Self-care: Week 12 — Severe Problems6411
Self-care: Week 12 — Extreme Problems200
Self-care: Week 24 — No Problems835845
Self-care: Week 24 — Slight Problems233131
Self-care: Week 24 — Moderate Problems131610
Self-care: Week 24 — Severe Problems444
Self-care: Week 24 — Extreme Problems010
Usual Activities: Week 4 — No Problems273822
Usual Activities: Week 4 — Slight Problems655044
Usual Activities: Week 4 — Moderate Problems263849
Usual Activities: Week 4 — Severe Problems191225
Usual Activities: Week 4 — Extreme Problems864
Usual Activities: Week 12 — No Problems475126
Usual Activities: Week 12 — Slight Problems544148
Usual Activities: Week 12 — Moderate Problems253738
Usual Activities: Week 12 — Severe Problems151120
Usual Activities: Week 12 — Extreme Problems030
Usual Activities: Week 24 — No Problems514120
Usual Activities: Week 24 — Slight Problems453241
Usual Activities: Week 24 — Moderate Problems182824
Usual Activities: Week 24 — Severe Problems874
Usual Activities: Week 24 — Extreme Problems121
Pain/Discomfort: Week 4 — No Problems8113
Pain/Discomfort: Week 4 — Slight Problems695737
Pain/Discomfort: Week 4 — Moderate Problems455062
Pain/Discomfort: Week 4 — Severe Problems192236
Pain/Discomfort: Week 4 — Extreme Problems446
Pain/Discomfort: Week 12 — No Problems211610
Pain/Discomfort: Week 12 — Slight Problems685636
Pain/Discomfort: Week 12 — Moderate Problems345657
Pain/Discomfort: Week 12 — Severe Problems171428
Pain/Discomfort: Week 12 — Extreme Problems111
Pain/Discomfort: Week 24 — No Problems182010
Pain/Discomfort: Week 24 — Slight Problems614232
Pain/Discomfort: Week 24 — Moderate Problems313633
Pain/Discomfort: Week 24 — Severe Problems121014
Pain/Discomfort: Week 24 — Extreme Problems121
Anxiety/Depression: Week 4 — No Problems787760
Anxiety/Depression: Week 4 — Slight Problems334143
Anxiety/Depression: Week 4 — Moderate Problems252134
Anxiety/Depression: Week 4 — Severe Problems845
Anxiety/Depression: Week 4 — Extreme Problems112
Anxiety/Depression: Week 12 — No Problems798471
Anxiety/Depression: Week 12 — Slight Problems333034
Anxiety/Depression: Week 12 — Moderate Problems232623
Anxiety/Depression: Week 12 — Severe Problems533
Anxiety/Depression: Week 12 — Extreme Problems101
Anxiety/Depression: Week 24 — No Problems706250
Anxiety/Depression: Week 24 — Slight Problems333019
Anxiety/Depression: Week 24 — Moderate Problems161315
Anxiety/Depression: Week 24 — Severe Problems446
Anxiety/Depression: Week 24 — Extreme Problems010
SecondaryEQ-5D Current Health VAS at Weeks 4, 12, and 24

EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
EQ-5D Current Health VAS at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 459.0 ± 22.160.0 ± 19.852.0 ± 24.2
Week 1266.0 ± 23.265.0 ± 22.258.0 ± 23.0
Week 2470.0 ± 21.869.0 ± 21.362.0 ± 23.0
SecondaryChange From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24

The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline49.0 ± 24.746.0 ± 24.046.0 ± 22.4
Change from Baseline at Week 410.0 ± 27.614.0 ± 26.86.0 ± 26.0
Change from Baseline at Week 1217.0 ± 30.919.0 ± 26.412.0 ± 26.5
Change from Baseline at Week 2422.0 ± 30.825.0 ± 26.717.0 ± 25.4
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.009 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 6.0 · 95% CI 2.0 to 11.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.003 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 7.0 · 95% CI 3.0 to 12.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.003 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 8.0 · 95% CI 3.0 to 13.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.006 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 7.0 · 95% CI 2.0 to 12.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.002 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 9.0 · 95% CI 3.0 to 15.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.007 (MMRM model included treatment, visit (as categorical), treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 8.0 · 95% CI 2.0 to 14.0
SecondaryWork Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of work time missed
Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
percentage of work time missedFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 48.8 ± 21.0118.2 ± 30.9314.3 ± 27.52
Week 125.6 ± 13.7914.6 ± 27.1312.1 ± 24.39
Week 247.6 ± 16.3713.8 ± 26.238.5 ± 18.08
SecondaryWPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of impairment while working
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
percentage of impairment while workingFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 427.4 ± 22.5037.8 ± 25.4348.6 ± 29.81
Week 1223.9 ± 20.9934.8 ± 27.2244.2 ± 29.21
Week 2428.0 ± 27.5725.6 ± 22.1036.7 ± 26.95
SecondaryWPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of overall work productivity
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
percentage of overall work productivityFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 430.8 ± 24.3643.1 ± 27.8251.3 ± 30.85
Week 1226.9 ± 24.2039.5 ± 29.3746.9 ± 30.63
Week 2431.7 ± 29.9431.4 ± 25.6539.8 ± 29.49
SecondaryWPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of activity impairment
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
percentage of activity impairmentFilgotinib 200 mgFilgotinib 100 mgPlacebo
Week 449.6 ± 26.5649.9 ± 27.4360.3 ± 25.49
Week 1240.3 ± 26.7545.5 ± 28.2353.0 ± 27.26
Week 2433.3 ± 24.6137.5 ± 27.0045.7 ± 25.57
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of work time missed
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
percentage of work time missedFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline11.3 ± 16.3119.2 ± 28.5710.8 ± 25.65
Change from Baseline at Week 4-4.3 ± 20.98-3.4 ± 24.574.0 ± 20.75
Change from Baseline at Week 12-3.6 ± 17.60-7.0 ± 30.933.8 ± 18.40
Change from Baseline at Week 24-4.6 ± 22.50-3.1 ± 34.283.7 ± 25.13
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of impairment while working
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
percentage of impairment while workingFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline46.9 ± 24.7151.0 ± 27.9555.7 ± 26.64
Change from Baseline at Week 4-19.1 ± 25.63-13.1 ± 25.75-5.3 ± 25.52
Change from Baseline at Week 12-20.0 ± 25.56-18.8 ± 28.64-10.8 ± 20.32
Change from Baseline at Week 24-18.6 ± 22.48-28.7 ± 25.26-20.0 ± 31.36
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of overall work productivity
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
percentage of overall work productivityFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline52.0 ± 24.0255.8 ± 30.5356.7 ± 27.60
Change from Baseline at Week 4-20.9 ± 28.94-12.3 ± 28.05-3.4 ± 25.48
Change from Baseline at Week 12-22.8 ± 29.20-19.5 ± 31.49-8.3 ± 20.16
Change from Baseline at Week 24-20.5 ± 26.20-26.4 ± 29.87-16.7 ± 33.28
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of activity impairment
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
percentage of activity impairmentFilgotinib 200 mgFilgotinib 100 mgPlacebo
Baseline65.6 ± 22.1664.6 ± 23.0765.4 ± 23.33
Change from Baseline at Week 4-16.0 ± 24.64-14.3 ± 22.89-4.7 ± 25.06
Change from Baseline at Week 12-25.0 ± 26.81-19.2 ± 28.32-11.3 ± 25.75
Change from Baseline at Week 24-32.5 ± 27.37-27.1 ± 27.97-18.4 ± 31.23

Adverse events

Collected over First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib 200 mg0/147 (0%)6/147 (4.1%)39/147 (26.5%)
Filgotinib 100 mg0/153 (0%)8/153 (5.2%)35/153 (22.9%)
Placebo0/148 (0%)5/148 (3.4%)31/148 (20.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
GastroenteritisInfections and infestations0/1470/1532/148
VertigoEar and labyrinth disorders1/1470/1530/148
DiarrhoeaGastrointestinal disorders1/1470/1530/148
CellulitisInfections and infestations1/1470/1530/148
ConcussionInjury, poisoning and procedural complications1/1470/1530/148
LacerationInjury, poisoning and procedural complications1/1470/1530/148
Rib fractureInjury, poisoning and procedural complications1/1470/1530/148
DehydrationMetabolism and nutrition disorders1/1470/1531/148
Lactic acidosisMetabolism and nutrition disorders1/1470/1530/148
BursitisMusculoskeletal and connective tissue disorders1/1470/1530/148
Most frequent other events
Most frequent other events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
NasopharyngitisInfections and infestations15/1479/1537/148
Upper respiratory tract infectionInfections and infestations8/1479/1536/148
HeadacheNervous system disorders8/1479/1532/148
BronchitisInfections and infestations8/1473/1538/148
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/1472/1538/148
NauseaGastrointestinal disorders7/1478/1535/148

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Mean56.0 ± 12.555.0 ± 12.056.0 ± 12.156.0 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Female120119121360
Male27342788
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Race — American Indian or Alaska Native791026
Race — Asian: Japanese12151340
Race — Asian: Chinese/Taiwanese/Hong Kong Chinese0000
Race — Asian: Vietnamese1001
Race — Asian: Korean2215
Race — Asian: Other0314
Race — Black or African American14122147
Race — Native Hawaiian or Pacific Islander0000
Race — White11010997316
Race — Other1326
Race — Not Permitted0033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Ethnicity — Hispanic or Latino264041107
Ethnicity — Not Hispanic or Latino120112107339
Ethnicity — Not Permitted1102
Region of Enrollment
Region of Enrollment(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
United States878484255
Spain47516
Germany84315
Belgium43613
France2259
United Kingdom2529
South Korea2215
Australia1124
Israel0123
Switzerland1102
Poland75719
Hungary57416
Mexico813930
Argentina43512
Japan12151340
08

Study locations

104 sites
  • Huntsville, Alabama, United States
  • Gilbert, Arizona, United States
  • Covina, California, United States
  • Hemet, California, United States
  • La Jolla, California, United States
  • Palm Desert, California, United States
  • Palo Alto, California, United States
  • Riverside, California, United States
  • Upland, California, United States
  • Victorville, California, United States
  • Whittier, California, United States
  • Aventura, Florida, United States
  • DeBary, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Plantation, Florida, United States
  • Port Richey, Florida, United States
  • Decatur, Georgia, United States
  • Kansas City, Kansas, United States
  • Wichita, Kansas, United States
  • Elizabethtown, Kentucky, United States
  • Lexington, Kentucky, United States
  • Cumberland, Maryland, United States
  • Frederick, Maryland, United States
  • Worcester, Massachusetts, United States
  • Detroit, Michigan, United States
  • Saint Clair Shores, Michigan, United States
  • Hattiesburg, Mississippi, United States
  • Tupelo, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Lebanon, New Hampshire, United States
  • Freehold, New Jersey, United States
  • Toms River, New Jersey, United States
  • Brooklyn, New York, United States
  • Charlotte, North Carolina, United States
  • Greenville, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Middleburg Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Wyomissing, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Columbia, South Carolina, United States
  • Myrtle Beach, South Carolina, United States
  • Orangeburg, South Carolina, United States
  • Memphis, Tennessee, United States
  • Beaumont, Texas, United States
  • Corpus Christi, Texas, United States
  • Mesquite, Texas, United States
  • Plano, Texas, United States
  • San Antonio, Texas, United States
  • Webster, Texas, United States
  • Buenos Aires, Argentina
  • Caba, Argentina
  • San Juan, Argentina
  • Victoria Park, Western Australia, Australia
  • Gent, Belgium
  • Leuven, Belgium
  • Merksem, Belgium
  • Montpellier, France
  • Berlin, Germany
  • Hamburg, Germany
  • Ratingen, Germany
  • Budapest, Hungary
  • Gyula, Hungary
  • Székesfehérvár, Hungary
  • Haifa, Israel
  • Ramat Gan, Israel
  • Hiroshima, Japan
  • Izumo, Japan
  • Katō, Japan
  • Kawagoe, Japan
  • Kumamoto, Japan
  • Narashino, Japan
  • Okayama, Japan
  • Sagamihara, Japan
  • Sapporo, Japan
  • Shinjuku-Ku, Japan
  • Takaoka, Japan
  • Takasaki, Japan
  • Tokorozawa, Japan
  • Tokyo, Japan
  • Tomigusuku, Japan
  • Seoul, Korea, Republic of
  • Chihuahua, Mexico
  • Distrito Federal, Mexico
  • Mérida, Mexico
  • Białystok, Poland
  • Poznań, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Madrid, Spain
  • Málaga, Spain
  • Sabadell, Spain
  • Valencia, Spain
  • Sankt Gallen, Switzerland
  • Doncaster, United Kingdom

Showing the first 100 of 104 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Genovese MC, Kalunian KC, Walker D, Gottenberg JE, De Vlam K, Mozaffarian N, et al. Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards [Abstract No. L06]. ACR/ARHP Annual Meeting; 2018 19-24 October; Chicago, IL, USA.
  • Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055. Erratum In: JAMA. 2020 Feb 4;323(5):480. doi: 10.1001/jama.2019.21742. PubMed 31334793 ↗
  • Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7. PubMed 36205910 ↗
  • Bingham CO 3rd, Walker D, Nash P, Lee SJ, Ye L, Hu H, Khalid JM, Combe B. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Arthritis Res Ther. 2022 Jan 3;24(1):11. doi: 10.1186/s13075-021-02677-7. PubMed 34980223 ↗
  • Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Genovese MC, Kalunian K, Walker D, Gottenberg JE, de Vlam K, Bartok B, Pechonkina A, Kondo A, Gao J, Guo Y, Tasset C, Sundy JS, Tanaka Y. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). Mod Rheumatol. 2022 Jan 5;32(1):59-67. doi: 10.1080/14397595.2020.1859675. PubMed 33274687 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Mar 2018, 19 months.

Results were first posted in Jan 2021, 2 years 9 months after primary completion. A results delay was requested in Mar 2019.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2016
First posted
Aug 22, 2016
StartActual
Jul 27, 2016
Primary completionActual
Mar 20, 2018
CompletionActual
Jun 26, 2018
Results delay requested
Mar 13, 2019
Results first posted
Jan 15, 2021
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02873936
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Aug 22, 2016
Start date
Jul 27, 2016
Primary completion
Mar 20, 2018
Completion
Jun 26, 2018
Results posted
Jan 15, 2021
Last update
May 13, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion